Evaluation of Imiquimod 5% Cream to Modify the Natural History of Herpes Labialis: A Pilot Study | Zendy

David I. Bernstein | Zendy; Spotswood L. Spruance | Zendy; Sandeep Arora | Zendy; John Schroeder | Zendy; Tze Chiang Meng | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Imiquimod 5% Cream to Modify the Natural History of Herpes Labialis: A Pilot Study

Author(s) -

David I. Bernstein,

Spotswood L. Spruance,

Sandeep Arora,

John Schroeder,

Tze Chiang Meng

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/432802

Subject(s) - imiquimod , medicine , herpes labialis , erythema , dermatology , lesion , adverse effect , placebo , edema , surgery , immunology , pathology , virus , herpes simplex virus , alternative medicine

Imiquimod is currently approved for the treatment of genital warts and has been shown to decrease recurrences of genital herpes in the guinea pig model of genital herpes. Therefore, we evaluated the safety and potential of topical imiquimod to decrease the rate of recurrence in humans with a history of recurrent herpes labialis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research